Abstract: An externally-used solution containing chlorine dioxide for promoting hair growth is composed of chlorine dioxide or its precursors, pH regulators, medical solvents and plant extract in a certain weight ratio. The product may take the forms of a single solution containing chlorine dioxide or several solutions containing a chlorine dioxide precursor. The safety and effective oxidation sterilization and tissue regeneration ability of chlorine dioxide are introduced into the solution system for promoting hair growth, and the steps of removing hair loss factors, stimulating the growth of hair follicles, anti-inflammatory and anti-dandruff are done synchronously. Complemented medical solvents and plant extracts will change alopecia environment.

Abstract: The invention relates to a cosmetic composition in particular in the form of an emulsion for topical application to keratin materials, in particular the skin, comprising, in a physiologically acceptable medium: (i) at least one dispersion (pre-dispersion) of bismuth oxychloride (CI 77163) in an oily dispersant chosen from a) monoesters of formula R1COOR2 in which R1 represents a linear or branched hydrocarbon-based chain comprising from 4 to 40 carbon atoms, preferably from 4 to 30 carbon atoms, and preferentially from 7 to 20 carbon atoms, and R2 represents a branched hydrocarbon-based chain containing from 3 to 40 carbon atoms, preferably from 10 to 30 carbon atoms, and preferentially from 16 to 26 carbon atoms; b) oils whose solubility parameter at 25° C., ?a, is greater than 6 (J/cm3)1/2, and mixtures thereof, and (ii) at least one oil chosen from hydrocarbon-based oils having a refractive index greater than 1.42 and a solubility parameter at 25° C.

Abstract: The present invention relates to a peroxydisulfate oxidizing system for toothpaste compositions that provides excellent bleaching effect together with oral care compositions containing the oxidizing system and methods and uses therefor.

Abstract: The present invention provides an oral care composition comprising, by total weight of the composition: (a) 15 to 35 weight % calcium carbonate; (b) 0.5 to 2 weight % cellulose ether thickening agent; (c) 1 to 6 weight % clay thickening agent; and (d) at least 35 weight % water; wherein, when the composition comprises less than 28 weight % calcium carbonate and less than 4 weight % clay thickening agent, the cellulose ether thickening agent is present in an amount of greater than 1 weight %.

Abstract: The present invention provides an oral care composition comprising, based on the total weight of the composition: (a) 15 to 24 weight % calcium carbonate; (b) 0.9 to 2.5 weight % cellulose ether thickening agent; (c) 7 to 10 weight % thickening silica; and (d) at least 40 weight % water.

Abstract: An apparatus and method for providing cosmetic treatment to skin comprise one material chemically active in a solid form preferably in a tablet form and a second material which is chemically reactive with the first material so that effervescence is produced during the reaction. The chemically active materials may be activated by a user for providing cosmetic treatment to skin. The activation releases effervescence which urges granules of the reacting materials onto the skin. The size of the granules lowers during the reaction thus providing continuously refining peeling to the skin.

Abstract: Disclosed is a cosmetic conditioning oil composition comprising of an oil or mixture of oils having surface tension in the range of 26 dyne/cm or lower and an oil thickener, wherein the composition has a viscosity about 5,000 cps or higher at 25 degrees Celsius. The composition of the present invention can provide improved conditioning benefits such as smoothness, softness, and ease of combing for hair when applied in shampoos, conditioner, treatments, and skin cleansing products as a silicone alternative.

Abstract: The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).

Abstract: A method for oral health treatment of a subject using a composition having an anti-oxidant enzyme, an anti-inflammatory agent, and a pharmaceutically acceptable buffer. In certain embodiments, the compositions are administered to the subject in conjunction with teeth whitening, oral surge oral pathology treatment, endodontic therapy, periodontal therapy, dental restoration, preventative tooth cleaning, or subsequent to a pro-oxidant.

Abstract: The present invention relates to a composition for promoting hair restoration and/or hair growth comprising a sulfa agent and a chitosan agent. In addition, the present invention is to provide a kit comprising the composition for promoting hair restoration and/or hair growth and a method comprising a step of applying the composition for promoting hair restoration and/or hair growth of the present invention. According to the present invention, a composition for promoting hair restoration and/or hair growth having a remarkable effect can be provided.

Abstract: Provided are hair care compositions comprising: (a) a polyolefin oil blend comprising (i) at least one metallocene catalyzed polyolefin with a density above 0.90 g/cm3, (ii) at least one metallocene catalyzed polyolefin with a density equal to or below 0.90 g/cm3, and (iii) a cosmetically acceptable hydrocarbon oil; (b) a thickener; and (c) a humectant; wherein the high and low density polyolefins have an average melt index greater than 7, wherein the polyolefin blend is present in a range of from 0.1 to 1.4 weight % by weight of the composition, and wherein the composition is substantially free of ethylene-acrylic acid copolymer.

Abstract: Inventive embodiments disclosed herein include a water-based formulation that includes silane-modified Styrene/acrylic ester copolymer in a concentration of 29.0 percent by weight; polycarbonate polyurethane dispersion in a concentration of 5.0 percent by weight; propylene glycol butyl ether in a concentration of 3.0 percent by weight; and water in a concentration of at least about 53.0 percent by weight.

Abstract: Hairstyling compositions which provide the user with continuous wave fizz-free hairstyling using only low heat (such as that applied by a blow dryer) and a round hair brush as well as a natural feel to the hair is disclosed. The compositions incorporate a mixture of two and preferably three polymers, those polymers including an organopolysiloxane graft polymer, a graft polymer comprising polyacrylate (such as polyacrylate-32), and optionally a water-soluble silicone polymer (such as bis-PEG-8-dimethicone). The method of using these compositions to provide the desired hairstyles is also disclosed.

Abstract: A composition having three components. The first component is a vegetable oil. The second component is an aliphatic quaternary ammonium salt having from five to twenty carbon atoms and from two to six hydroxyl groups. The third component is a surfactant package.

Abstract: Cosmetic compositions are provided that include an extract from a seed of the Nicotiana species, one or more cosmetically acceptable carriers to act as a diluent, dispersant or carrier for the composition, and optionally one or more cosmetic adjuvants. The tobacco seed extract is typically characterized as having a significant lipid content and, thus, finds use as an oil component in a cosmetic composition.

Abstract: Disclosed is a composition containing an extract of alpine wormwood (Artemisia Umbelliformis) as an active ingredient. The composition disclosed in the present specification has the effect of reducing melanin generation, or inhibiting activation of tyrosinase due to the composition containing the extract of an alpine wormwood (Artemisia Umbelliformis). Accordingly, due to such effects, the alpine wormwood (Artemisia Umbelliformis) extract of the present specification can exhibit a whitening effect, and thus can be widely used in the pharmaceutical or cosmetics fields as a whitening composition.

Abstract: A ferment extract of a bacterial strain of the Bacillus pumilus species, a method of treatment and/or care of the skin and/or muscles, and cosmetic and/or dermopharmaceutical compositions containing the ferment extract. In particular, the ferment extract is used for muscular endurance, wound healing and skin firmness.

Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Abstract: Provided is a microneedle. The microneedle array includes a needle portion, which contains an inactivated whole virion influenza vaccine, and a sheet portion. Also provided is an administration method in which the microneedle array is administered and then administered secondly after an interval of equal to or greater than 24 hours and less than 2 months.

Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of a biodegradable drug depot film, patch, strip or sponge being implantable at or near a cardiac tissue or within a nasal or sinus cavity, one can reduce, prevent or treat pain and/or inflammation.

Abstract: The present invention provides a nasal vaccine for Streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.

Abstract: A tear substitute having hyaluronan has a viscoelastic flow characteristics with the zero shear viscosity being ?50 mPa·s, and the shear viscosity at 1000 s?1 being ?12 mPa·s or having hyaluronan with an intrinsic viscosity [?]>2.5 m3/kg and a concentration of <0.2% w/v. A fluid with the aforementioned specifications is used as a tear substitute. A method of producing a tear substitute comprises the use of substances for reaching a viscoelastic flow characteristics with the zero shear viscosity being 50 mPa·s, and the shear viscosity at 1000 s?1 being ?12 mPa·s. Alternatively the inventive method comprises the use of hyaluronan with an intrinsic viscosity [?]>2.5 m3/kg and a concentration of <0.2% w/v.

Abstract: Orally disintegrating medicaments comprising Nabilone allow for improved treatment of nausea arising from chemo therapy for cancer. The medicaments comprise appropriate excipients such that the medicament disintegrates in the mouth in 30 seconds or less, while exhibiting sufficient stability for storage. In a preferred embodiment, the medicament is in the form of a tablet formed from granules. The granules consist of an intra-granular fraction comprising nabilone, mannitol, and polyvinyl pyrrolidone and an extra-granular fraction comprising mannitol, calcium silicate, crospovidone, and magnesium stearate. Processes for manufacturfing such medicaments are also disclosed.

Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.

Abstract: Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.

Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, nm) of 100-500 nm, where the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc.

Abstract: A drug carrier and a manufacturing method thereof are provided. The drug carrier includes a hydrophilic group, a hydrophobic group and an organic dye. The hydrophilic group and the hydrophobic group are connected by the organic dye. A plurality of the drug carriers are self-assemblable in a polar solvent to form a nanomicelle. The hydrophilic groups are located at the outer region of the nanomicelle, and the hydrophobic groups are located at the inner region of the nanomicelle.

Abstract: This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule.

Abstract: An improved spray drying method for production of amorphous solid dispersions with enhanced bulk density and material attributes comprising the introduction of at least one additional stream in at least one of multiple locations in a spray dryer without interfering with the spray region.

Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

Abstract: Methods for inhibiting tissue ossification or calcification in a subject, comprising administering a therapeutically effective amount of BMP I inhibitor-loaded microparticles to a subject in need thereof, wherein the administration provides local and sustained release of the BMP I inhibitor thereby inhibiting tissue ossification or calcification.

Abstract: The present disclosure relates to a polymer-coated virus particle for an oral virus vaccine, a method of preparing the same, and a composition comprising the same. In accordance with the present disclosure, the oral virus vaccine can be effectively delivered to the intestines without being destroyed even in the low pH environment of the gastrointestinal tract, then the prevention efficacy against viral infections can be improved.

Abstract: Provided are protein polymers providing the dual functionality of delivery and imaging. The protein polymers comprise a coiled-coil domain of the cartilage oligomeric matrix protein and repeats of elastic like peptides. The coiled-coil domain allows delivery of molecules, the elastin-like peptide domain provides thermo-responsive functionality, and a plurality of leucine residues, which can be fluorinated, provide imaging functionality.

Abstract: The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-1500, and a method for preparing the same.

Abstract: The purpose of the present invention is to provide a nonaqueous tape that is stable and has high percutaneous absorption performance, and that contains pramipexole hydrochloride, which is slightly soluble in organic solvents and has high crystallinity. The present invention could produce a nonaqueous tape that is stable and has high percutaneous absorption performance by dissolving pramipexole, using a combination of a fatty acid ionic liquid and a divalent alcohol and a fatty acid ester. As a result, it has become possible to provide a transdermal patch (tape) containing pramipexole for the treatment of Parkinson's disease with which the problems associated with a conventional water-containing poultice of discoloration of the preparation and stability of the pramipexole can be solved.

Abstract: A composition comprising a pharmaceutically effective amount of zeaxanthin or its derivative for use in treating a malignant tumor and a method of using a pharmaceutically effective amount of zeaxanthin or its derivative either alone or together with one or more pharmaceutical agents for treating a malignant tumor. The tumor may be, but is not limited to breast cancer, cervix cancer, colon cancer, cutaneous melanoma, cutaneous squamous carcinoma, hepatocellular carcinoma, lung cancer, osteosarcoma, prostate cancer, and uveal melanoma. The pharmaceutically effective amount of zeaxanthin is generally above about 0.5 mg/kg/d to about 20 mg/kg/d.

Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.

Abstract: Disclosed herein are methods for enhancing the immune response of a companion animal, comprising administering to a companion animal a composition comprising an effective amount of astaxanthin.

Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being.

Abstract: The invention relates to a composition for enhancing wound healing and/or for reducing pain and inflammation, comprising a first active ingredient and a second active ingredient, wherein the first active ingredient comprises an antiseptic and the second active ingredient comprises an admixture of at least one vitamin, at least one mineral and at least one amino acid, and to use of the composition for enhancing wound healing.

Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.

Abstract: Methods of killing or inhibiting the growth cancer cells and tumors and of treating cancer by administering compounds that stimulate the activity of RAD51. Cells overexpressing RAD51 or with other imbalances in homologous recombination machinery are particularly susceptible targets of RAD51 stimulators.

Abstract: A mitochondria targeted gold nanoparticle (T-3-BP-AuNP) decorated with 3-bromopyruvate (3-BP) and delocalized lipophilic triphenylphosphonium (TPP) cations to target the mitochondrial membrane potential (??m) was developed for delivery of 3-BP to cancer cell mitochondria by taking advantage of higher ??m in cancer cell compared to normal cells. This construct showed remarkable anticancer activity in prostate cancer cells compared to non-targeted construct NT-3-BP-AuNP and free 3-BP. Anticancer activity of T-3-BP-AuNP was further enhanced upon laser irradiation by exciting the surface plasmon resonance band of AuNP and thereby utilizing a combination of 3-BP chemotherapeutic and AuNP photothermal effects. T-3-BP-AuNPs showed markedly enhanced ability to alter cancer cell metabolism by inhibiting glycolysis and demolishing mitochondrial oxidative phosphorylation in prostate cancer cells.

Abstract: The present invention provides novel compounds with hypocholesteremic activity from crude Embilica officinialis (EO) extracts and methods of use. The invention also provides nutraceuticals.

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: The present invention relates to an endoprosthesis with a drug coating comprising or consisting of at least one antibiotic agent and at least one further substance having the following general

Abstract: A fatty acid composition comprising at least one purified very long chain saturated fatty acid (VLC-SFA) having a chain length in a range of from about 28 carbons to about 40 carbons which is conjugated to a carrier molecule, forming a VLC-SFA-carrier conjugate. Nutritional supplements containing the fatty acid compositions, and methods of producing and using the fatty acid compositions, are also disclosed.

Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.